Sub menu

 
 

Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia

We have adopted this International Scientific Guideline - EMA/CHMP/153191/2013 

Last updated

About this guideline

Overseas effective date:  1 September 2014

Categories: Clinical efficacy and safety | Antineoplastic and immunomodulating agents, and Clinical efficacy and safety | blood and blood-forming organs

TGA Annotations: Nil
 

  • Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
  • All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

For more information see International scientific guidelines adopted in Australia.

Topics

Help us improve the Therapeutic Goods Administration site